Mark Lunt

24.1k total citations · 3 hit papers
353 papers, 15.9k citations indexed

About

Mark Lunt is a scholar working on Rheumatology, Immunology and Hematology. According to data from OpenAlex, Mark Lunt has authored 353 papers receiving a total of 15.9k indexed citations (citations by other indexed papers that have themselves been cited), including 154 papers in Rheumatology, 62 papers in Immunology and 51 papers in Hematology. Recurrent topics in Mark Lunt's work include Rheumatoid Arthritis Research and Therapies (135 papers), Systemic Lupus Erythematosus Research (66 papers) and Autoimmune and Inflammatory Disorders Research (49 papers). Mark Lunt is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (135 papers), Systemic Lupus Erythematosus Research (66 papers) and Autoimmune and Inflammatory Disorders Research (49 papers). Mark Lunt collaborates with scholars based in United Kingdom, United States and Germany. Mark Lunt's co-authors include Deborah Symmons, Kimme L Hyrich, Alan J. Silman, Kath Watson, William G Dixon, James Galloway, Diane Bunn, Louise Mercer, Andrew Ustianowski and Terence W O’Neill and has published in prestigious journals such as The Lancet, JAMA and SHILAP Revista de lepidopterología.

In The Last Decade

Mark Lunt

342 papers receiving 15.4k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Rates of serious infection, including site‐specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti–tumor necrosis factor therapy: Results from the British Society for Rheumatology Biologics Register

2006 534 citations William G Dixon, Mark Lunt et al. profile →
Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR)

2009 532 citations William G Dixon, Mark Lunt et al. profile →
Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly

2010 496 citations William G Dixon, Mark Lunt et al. Lara D. Veeken profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Mark Lunt	7.0k	3.4k	2.6k	2.5k	1.9k	353	15.9k
Loreto Carmona	7.3k 1.1×	2.6k 0.8×	2.5k 1.0×	2.5k 1.0×	1.4k 0.7×	370	14.0k
María E. Suarez‐Almazor	6.2k 0.9×	2.5k 0.7×	4.9k 1.9×	5.2k 2.1×	1.7k 0.9×	404	24.1k
Laure Gossec	10.0k 1.4×	3.7k 1.1×	4.1k 1.6×	1.9k 0.8×	1.4k 0.7×	529	14.8k
Hilal Maradit Kremers	9.8k 1.4×	2.8k 0.8×	1.6k 0.6×	6.8k 2.8×	1.1k 0.6×	210	20.4k
Michael M. Ward	8.5k 1.2×	4.1k 1.2×	2.0k 0.8×	1.9k 0.8×	1.5k 0.8×	290	14.2k
Maarten Boers	14.5k 2.1×	2.6k 0.8×	5.1k 2.0×	4.4k 1.8×	3.2k 1.6×	468	32.7k
Janet Pope	7.9k 1.1×	4.2k 1.2×	2.0k 0.8×	2.1k 0.8×	7.2k 3.7×	512	19.0k
John M. Esdaile	6.6k 1.0×	2.1k 0.6×	1.7k 0.7×	2.1k 0.9×	1.7k 0.9×	272	13.6k
Sherine E. Gabriel	16.4k 2.4×	4.1k 1.2×	3.2k 1.3×	5.3k 2.2×	2.4k 1.2×	202	29.3k
Steven M. Edworthy	15.9k 2.3×	4.4k 1.3×	3.7k 1.4×	2.1k 0.8×	2.6k 1.4×	51	24.6k

Countries citing papers authored by Mark Lunt

Since Specialization

Citations

This map shows the geographic impact of Mark Lunt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Lunt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Lunt more than expected).

Fields of papers citing papers by Mark Lunt

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Lunt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Lunt. The network helps show where Mark Lunt may publish in the future.

Co-authorship network of co-authors of Mark Lunt

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Lunt. A scholar is included among the top collaborators of Mark Lunt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Lunt. Mark Lunt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Descalzo, M.Á., Mahmoud Zureik, R. Rivera, et al.. (2024). Drug survival and safety of biosimilars for treating psoriasis compared with originator adalimumab: a multinational cohort study. British Journal of Dermatology. 192(4). 641–652. 1 indexed citations

McBeth, John, et al.. (2024). Use of over-the-counter supplements, sleep aids and analgesic medicines in rheumatology: results of a cross-sectional survey. Rheumatology Advances in Practice. 8(4). rkae129–rkae129. 1 indexed citations

Lunt, Mark, et al.. (2023). Day-to-day variability of knee pain and the relationship with physical activity in people with knee osteoarthritis: an observational, feasibility study using consumer smartwatches. BMJ Open. 13(3). e062801–e062801. 4 indexed citations

Jani, Meghna, et al.. (2023). “Take up to eight tablets per day”: Incorporating free‐text medication instructions into a transparent and reproducible process for preparing drug exposure data for pharmacoepidemiology. Pharmacoepidemiology and Drug Safety. 32(6). 651–660. 11 indexed citations

Bewley, Anthony, Catherine Smith, Teena Mackenzie, et al.. (2023). Uptake of tumour necrosis factor-alpha inhibitor biosimilars for psoriasis: a drug utilization study from the British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR). British Journal of Dermatology. 189(1). 62–70. 3 indexed citations

Zureik, Mahmoud, R. Rivera, Antonio Sahuquillo‐Torralba, et al.. (2023). Drug survival and safety of biosimilars and originator adalimumab in the treatment of psoriasis: a multinational cohort study. BMJ Open. 13(7). e075197–e075197. 3 indexed citations

Huang, Yun-Ting, David Jenkins, Belay Birlie Yimer, et al.. (2023). Trends for opioid prescribing and the impact of the COVID-19 pandemic in patients with rheumatic and musculoskeletal diseases between 2006 and 2021. Lara D. Veeken. 63(4). 1093–1103. 8 indexed citations

McBeth, John, William G Dixon, Bruce Hellman, et al.. (2021). Sleep Disturbance and Quality of Life in Rheumatoid Arthritis: Prospective mHealth Study. Journal of Medical Internet Research. 24(4). e32825–e32825. 20 indexed citations

Mason, K.J., A. David Burden, Juliet N. Barker, et al.. (2021). Characteristics and skin cancer risk of psoriasis patients with a history of skin cancer in BADBIR. Journal of the European Academy of Dermatology and Venereology. 35(8). e498–e501. 4 indexed citations

10.

Reynolds, John A., et al.. (2021). Distinct patterns of disease activity over time in patients with active SLE revealed using latent class trajectory models. Arthritis Research & Therapy. 23(1). 203–203. 5 indexed citations

11.

Mason, K.J., A. David Burden, Juliet N. Barker, et al.. (2021). Risks of basal cell and squamous cell carcinoma in psoriasis patients after treatment with biologic vs non‐biologic systemic therapies. Journal of the European Academy of Dermatology and Venereology. 35(8). e496–e498. 3 indexed citations

12.

Yiu, Zenas Z N, K.J. Mason, Philip Hampton, et al.. (2020). Drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis: a prospective cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR). British Journal of Dermatology. 183(2). 294–302. 74 indexed citations

13.

Yiu, Zenas Z N, Rosa Parisi, Mark Lunt, et al.. (2020). Risk of hospitalization and death due to infection in people with psoriasis: a population‐based cohort study using the Clinical Practice Research Datalink*. British Journal of Dermatology. 184(1). 78–86. 23 indexed citations

14.

Jani, Meghna, Belay Birlie Yimer, Thérèse Sheppard, Mark Lunt, & William G Dixon. (2020). Time trends and prescribing patterns of opioid drugs in UK primary care patients with non-cancer pain: A retrospective cohort study. PLoS Medicine. 17(10). e1003270–e1003270. 94 indexed citations

15.

Yiu, Zenas Z N, K.J. Mason, Juliet N. Barker, et al.. (2019). A standardization approach to compare treatment safety and effectiveness outcomes between clinical trials and real‐world populations in psoriasis. British Journal of Dermatology. 181(6). 1265–1271. 16 indexed citations

16.

Cook, Michael J., et al.. (2019). Effect of Timing and Duration of Statin Exposure on Risk of Hip or Knee Revision Arthroplasty: A Population-based Cohort Study. The Journal of Rheumatology. 47(3). 441–448. 18 indexed citations

17.

Yiu, Zenas Z N, Darren M. Ashcroft, Ian Evans, et al.. (2018). Infliximab is associated with an increased risk of serious infection in patients with psoriasis in the U.K. and Republic of Ireland: results from the British Association of Dermatologists Biologic Interventions Register ( BADBIR ). British Journal of Dermatology. 180(2). 329–337. 26 indexed citations

18.

Joseph, Rebecca M., Tjeerd van Staa, Mark Lunt, Michał Abrahamowicz, & William G Dixon. (2018). Exposure measurement error when assessing current glucocorticoid use using UK primary care electronic prescription data. Pharmacoepidemiology and Drug Safety. 28(2). 179–186. 13 indexed citations

19.

Yiu, Zenas Z N, Catherine Smith, Darren M. Ashcroft, et al.. (2017). Risk of Serious Infection in Patients with Psoriasis Receiving Biologic Therapies: A Prospective Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). Journal of Investigative Dermatology. 138(3). 534–541. 49 indexed citations

20.

Lunt, Mark, et al.. (2005). Increasing age at symptom onset is strongly associated with worse radiologic damage both at presentation and follow-up in an inception cohort of patients with inflammatory polyarthritis. UEA Digital Repository (University of East Anglia). 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact